Rappta
4 known investors
Find your way into Rappta
Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function. The company targets the underlying mechanism of protein hyperphosphorylation that drives cancer progression.
Investors · 4
Advent Life SciencesLondon
Novartis Venture Fundreported · 2 sourcesBasel · $5M – $25M
Novo Holdingsreported · 2 sourcesCopenhagen · $1.1M – $54M
Also in the syndicate · 1
Novo Seedslead
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AOct 2020
Novartis Venture Fund (lead), Novo Holdings (lead), Novo Seeds (lead), Advent Life Sciences
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Rappta do?
- Rappta Therapeutics develops small molecule compounds that reactivate protein phosphatase 2A (PP2A) to treat cancer by restoring the enzyme's tumor suppressor function. The company targets the underlying mechanism of protein hyperphosphorylation that drives cancer progression.
- Who are Rappta's investors?
- Rappta's investors include Advent Life Sciences, Novartis Venture Fund, Novo Holdings.